Skip to main content
S&P 5007,717.03+0.52%DOW52,375.19+0.03%NASDAQ26,453.11+1.08%BTC$80,544.00+0.50%ETH$2,345.35+1.00%GOLD$4,070.30+0.79%OIL$99.97-1.76%
Smart Investors Daily
SID Premium
PG

NASDAQ · PGEN

Precigen, Inc.

Healthcare · Biotechnology

$6.04

Up+$0.10 (+1.66%)

Updated Oct 27, 2026, 5:38 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.09B
P/E ratio
-2.51
Dividend yield
0.00%
52-week range
$3.04 – $8.98
Volume
2.55M
Avg. volume
4.88M

Price performance · PGEN

PGEN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

PGEN closed at $6.04 after 21 trading sessions, down 22.66% for the selected period.

Last close
$6.04
Period change
-22.66%
Period low
$6.04
Period high
$8.56
Daily close
View OHLC price history
PGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$6.24$6.3099$6.01$6.042.55M
Oct 23, 2026$6.35$6.38$6.15$6.194.35M
Oct 22, 2026$6.50$6.63$6.2801$6.396.25M
Oct 21, 2026$6.79$6.92$6.57$6.605.97M
Oct 20, 2026$6.62$6.945$6.51$6.836.17M
Oct 19, 2026$6.45$6.68$6.305$6.664.14M
Oct 16, 2026$7.19$7.22$6.305$6.3855.49M
Oct 15, 2026$7.31$7.55$7.17$7.1953.95M
Oct 14, 2026$7.48$7.70$7.33$7.3554.2M
Oct 13, 2026$7.60$7.71$7.48$7.482.4M
Oct 12, 2026$7.77$7.87$7.63$7.662.16M
Oct 9, 2026$7.595$7.8399$7.475$7.813.38M
Oct 8, 2026$7.49$7.64$7.40$7.603.83M
Oct 7, 2026$7.38$7.75$7.35$7.544.15M
Oct 6, 2026$7.79$7.90$7.4895$7.555.14M
Oct 5, 2026$8.51$8.60$7.55$7.7410.25M
Oct 2, 2026$8.30$8.55$8.18$8.546.36M
Oct 1, 2026$8.50$8.64$8.19$8.214.61M
Sep 30, 2026$8.13$8.98$8.09$8.5611.69M
Sep 29, 2026$7.80$8.10$7.80$8.054.14M
Sep 28, 2026$7.61$7.86$7.50$7.813.49M

Latest PGEN news

The latest Smart Investors Daily articles mentioning PGEN.

Stock researchCompany · Overview

PGEN research

Overview

Company profile and research snapshot.

Company profile

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
PGEN recent ratings
DateFirmRatingTarget
Sep 25, 2026B. Riley SecuritiesBuy—
Aug 5, 2026HC Wainwright & Co.Buy—
Aug 3, 2026HC Wainwright & Co.Buy—
May 28, 2026HC Wainwright & Co.Buy—
May 14, 2026CitizensMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Precigen (PGEN) Stock May Be Fully Priced On Its Huge 3 Year Run

Precigen has delivered a very large share price gain over the past few years, which naturally raises a sharper question for you as an investor. Is the current US$6.66 price adequately supported by the sales the business is generating today and what the market expects it to produce next? Over the past 3 years, Precigen has produced a very large share price return, so a lot of optimism about its commercial potential is already embedded in the debate around its sales base. The group’s future...

Yahoo · Oct 12, 2026

Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis

Patient Capital Management, based in Baltimore, released its third-quarter 2026 investor letter for the “Patient Opportunity Equity Strategy”. The letter can be downloaded here. The Opportunity Equity Strategy outperformed the S&P 500 in the latest quarter, gaining 4.32% compared to 2.30%, and is up 14.93% year-to-date versus the index’s 12.75%. The market shows resilience, despite rate […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By